Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01870895

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Diarrhea-predominant Irritable Bowel Syndrome Clinical Trial

Official title:
A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Clinical Trial Summary

To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel syndrome (D-IBS).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01870895
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Completed
Phase Phase 3
Start date February 2013
Completion date February 2014
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04095988 - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) N/A
Completed NCT01736423 - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome Phase 3
Completed NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients
Completed NCT01414244 - Glutamine for the Treatment of Patients With Irritable Bowel Syndrome Phase 2
Completed NCT03977155 - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT02163213 - Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D N/A
Terminated NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg Phase 3
Not yet recruiting NCT06346847 - Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS N/A
Not yet recruiting NCT05687435 - Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2/Phase 3
Recruiting NCT05593367 - Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
Completed NCT02538692 - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Phase 2/Phase 3
Completed NCT03099785 - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Phase 2
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Completed NCT01350570 - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Phase 2/Phase 3